...
首页> 外文期刊>Life sciences >Role of the non-neuronal cholinergic system in the eye. A review.
【24h】

Role of the non-neuronal cholinergic system in the eye. A review.

机译:非神经胆碱能系统在眼中的作用。回顾。

获取原文
获取原文并翻译 | 示例

摘要

Pharmacologically active preparations directed towards modulating muscarinic receptor activity in the eye have been used for over 2000 years when extracts from Atropa belladonna were first applied to enhance eye appearance through pupillary dilation. The first clinically active drugs targeting a specific eye disease were anticholinesterases (e.g. ecothiophate) applied as eye drops to treat glaucoma in the 1960's. However, cataract was soon detected as a relatively frequent side effect and such drugs are now only used to treat glaucoma as a last resort. As muscarinic agonists have been found to reduce intraocular pressure both by decreasing aqueous humour production (through Na,K-ATPase pump inhibition) and increasing outflow (by muscle contraction), it is likely that treatments will be developed that target specific muscarinic subtypes. Recently, it has been shown that the M1 receptor subtype predominates in the lens. It is therefore important that this subtype is not targeted in future ocular therapies so that the side-effect of cataract is avoided.Form-deprived myopia resulting from an increased axial length in the affected eye can be reduced by the application of atropine. This effect has been achieved both in a chick model system and in human clinical trials, and in the former system atropine has been shown to reduce the production of scleral extracellular proteins.Carbachol stimulates tear fluid production through the activation of muscarinic receptors. Interestingly, at least part of the stimulation occurs via epidermal growth factor (EGF) receptors and although the precise signalling mechanisms are not completely understood, it has been shown that calcium mobilisation plays a critical role in both muscarinic and EGF receptor activity.It should be noted that in the four examples described above, the cell types responsible for producing the physiological output are non-neuronal in origin. Therefore cholinergic receptor activation plays diverse roles in the eye and pharmacological intervention based on specific receptor sub-types has potential benefit in a number of ocular problems. However, potential side effects have also recently been identified.
机译:2000年以来,用于调节眼中毒蕈碱受体活性的药理活性制剂已被使用了2000多年,当时首次使用颠茄提取物通过瞳孔扩张来增强眼部外观。针对特定眼部疾病的首批临床活性药物是抗胆碱酯酶(例如ecothiophate),在1960年代用作滴眼剂治疗青光眼。然而,白内障很快被发现是一种相对频繁的副作用,这种药物现在仅被用于治疗青光眼。由于业已发现毒蕈碱激动剂可通过减少房水生成量(通过Na,K-ATPase泵抑制作用)和增加流出量(通过肌肉收缩)来降低眼内压,因此很有可能会开发针对特定毒蕈碱亚型的治疗方法。最近,已经显示出M1受体亚型在晶状体中占主导。因此,重要的是,该亚型在未来的眼部治疗中不要成为目标,这样可以避免白内障的副作用。阿托品的使用可以减少因患眼轴向长度增加而导致的缺乏形式的近视。在雏鸡模型系统和人体临床试验中均达到了这种效果,在前者系统中,阿托品已显示出减少巩膜细胞外蛋白的产生。卡巴胆碱通过毒蕈碱受体的激活刺激泪液的产生。有趣的是,至少部分刺激是通过表皮生长因子(EGF)受体发生的,尽管确切的信号传导机制尚不完全清楚,但已表明钙动员在毒蕈碱和EGF受体活性中都起着至关重要的作用。注意在上述四个例子中,负责产生生理输出的细胞类型是非神经源的。因此,胆碱能受体激活在眼睛中起着多种作用,基于特定受体亚型的药理学干预在许多眼部疾病中具有潜在的益处。但是,最近还发现了潜在的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号